<DOC>
	<DOCNO>NCT01291641</DOCNO>
	<brief_summary>The purpose study evaluate additional effect probucol concomitant administration cilostazol probucol mean carotid artery intima-media thickness ( mean IMT ) year 1 , 2 , 3 .</brief_summary>
	<brief_title>Investigate Effect Mean IMT Probucol And/or CilosTazol Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy</brief_title>
	<detailed_description>Hyperlipidemic patient currently receive HMGCoA reductase inhibitor ( Statins ) randomize Group A ( Control ) , Group B ( Probucol add group ) Group C ( Probucol cilostazol add group ) . Randomization do minimization method , control follow factor : Country ( Korea v China ) max IMT ( ≥2.0mm vs. &lt; 2.0mm ) . Group A : HMGCoA reductase inhibitor continue Group B : HMGCoA reductase inhibitor continue + Probucol 250 mg PO , BID Group C : HMGCoA reductase inhibitor continue + Probucol 250 mg PO , BID +Cilostazol 100 mg PO , BID</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 ) Subjects least 20 age time inform consent ( male female ) 2 ) Subjects coronary heart disease longer 3 month . 3 ) Subjects treat HMGCoA reductase inhibitor ( Statins ) 4 ) Subjects max IMT equal great 1.2 mm 5 ) Subjects LDLCholesterol le 200mg/dl 6 ) Subjects whose voluntary write informed consent obtain participation study 1 ) Subjects take probucol within 6 month participation study 2 ) Subjects take cilostazol within 3 month participation study 3 ) Subjects history hypersensitivity probucol cilostazol 4 ) Subjects homozygous familial hyperlipidemia* 5 ) Subjects triglyceride ( TG ) level great 400mg/dL screen 6 ) Subjects uncontrolled diabetes : HbA1c level great 9 % 7 ) Subjects New York Heart Association ( NYHA ) classification : Class Ⅲ Ⅳ 8 ) Subjects QTc interval great 450msec ( male ) 470msec ( female ) 9 ) Subjects serious ventricular arrythmias ( frequent episode multifocal ventricular extrasystole ) 10 ) Subjects atrial fibrillation ( include paroxysmal AF ) 11 ) Subjects unstable angina 12 ) Subjects liver kidney function satisfy follow criterion AST ALT &gt; 100 IU/L , serum creatinine &gt; 1.5 mg/dL 13 ) Subjects participate another clinical trial 14 ) Subjects pregnant possibly pregnant without appropriate contraception control . Appropriate contraception control mean Oral contraception great 4 week , surgical contraception include loop insertion , condom use etc . Women possibility pregnancy surgery menopause regard subject possibly pregnant 15 ) Subjects clinically significant disorder blood coagulation 16 ) Subjects consider physician appropriate participate trial reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
	<keyword>Probucol</keyword>
	<keyword>Cilostazol</keyword>
</DOC>